Search tips
Search criteria


Important Notice

PubMed Central Canada to be taken offline in February 2018

On February 23, 2018, PubMed Central Canada (PMC Canada) will be taken offline permanently. No author manuscripts will be deleted, and the approximately 2,900 manuscripts authored by Canadian Institutes of Health Research (CIHR)-funded researchers currently in the archive will be copied to the National Research Council’s (NRC) Digital Repository over the coming months. These manuscripts along with all other content will also remain publicly searchable on PubMed Central (US) and Europe PubMed Central, meaning such manuscripts will continue to be compliant with the Tri-Agency Open Access Policy on Publications.

Read more

Results 1-2 (2)

Clipboard (0)
more »
Year of Publication
Document Types
1.  Comparing Efficacy of Preoperative neo-Adjuvant Chemotherapy and Surgery versus Surgery Alone in Patients with Resectable Gastroesophageal Cancer 
Recent researches have led to find strategies to prevent relapse and to improve survival for gastric cancer patients, including preoperative neo-adjuvant approaches. However, the efficacy of some neo-adjuvant regimens including 5-fluorouracil, cisplatin, and docetaxel have been less investigated. The present study evaluated the outcome and mid-term survival of patients with gastric cancer who undergoing this regimen.
In a randomized double-blinded controlled trial performed at the Firoozgar hospital in Tehran in 2011-12, 61 patients were randomly assigned to treatment (32 to neo-adjuvant chemotherapy with docetaxel, cisplatin and 5-fluorouracil (5-FU) before surgery and 27 to surgery alone). The present study tried to assess the efficacy of neoadjuvant chemotherapy regarding improvement of mid-term survival, complications, and R0 resection status.
The two groups were matched in terms of gender, mean age, cancer location, and TNM staging. However, R0 resection in the former group was 85.7%; while this indicator in the isolated surgery group was significantly lower (61.5%). Regarding WHO performance, no significant difference was observed across the two groups. Patients in neo-adjuvant chemotherapy group were followed for mean follow-up time 10.32 months and those who categorized in isolated surgery group were followed for mean follow-up time 10.88 months. Mid-term mortality rate in the two groups was 14.3% and 15.4%, respectively (p = 0.866). In this regard, 3-, 6-, and 9-month survival rate in neo-adjuvant chemotherapy group was 96.4%, 89.3%, and 85.7%, respectively. These survival rates in the surgery group were 92.3%, 88.5%, and 84.6%, respectively. Multivariable logistic regression analysis showed that among all study variables, only R0 resection status could predict mid-term mortality.
Neo-adjuvant chemotherapy and surgery compare to surgery alone more improve R0 resection status, but mid-term survival rate is similar in the two regiments. R0 resection status can effectively predict appropriate mid-term survival in undertreated patients.
PMCID: PMC3915424  PMID: 24505539
Gastroesophageal junction; Mortality; Chemotherapy; Surgery
2.  Cyclooxygenase-2 Expression in Lymphoma in North-West of Iran 
Lymphomas are a group of malignancies affecting B, T and NK cells. Cyclooxygenase-2 (COX-2) enzyme is one of the known inflammatory factors which increase during the inflammation process. Increase in COX-2 expression inhibits apoptosis and increases tumor cells invasion and angiogenesis. Increase in the COX-2 gene expression is seen in a group of cancers. Specific COX-2 inhibition also can be beneficial in some cancers through apoptosis stimulation.
Materials & Methods
In this descriptive-analytic study, the degree of COX-2 expression was evaluated in patients with non-Hodgkin lymphoma. The following variables were used in this study: gender, age, lymphoma type, the stage of disease, the degree of disease, the existence of B symptom, extranodal involvement, response to treatment, death and LDH levels. Paraffin-embedded tissue blocks from 153 cases of non-Hodgkin’ and Hodgkin’ lymphoma were selected for immunohistochemical staining of COX-2 expression.
COX-2 level was reported positive in 4 (4.7%) patients with non-Hodgkin's lymphoma and 4 (5.7%) with Hodgkin's lymphoma. Fifteen patients experienced relapses and 9 died during the median follow-up of 7 years. There was no significant relationship between quantitative and qualitative variables and COX-2 expression. Also, there was no relationship between COX-2 and type of lymphoma (P=0.476).
According to our results, no relationship between COX-2 expression and type of lymphoma was found. We recommend more patient involvement to assess COX-2 expression. Apparently, it seems that the patient's race (Azari) may have an impact on the results of this study.
PMCID: PMC3913135  PMID: 24505512
COX-2; Non-Hodgkin lymphoma; Hodgkin lymphoma

Results 1-2 (2)